The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
about
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.HER2 testing: a review of detection methodologies and their clinical performanceAdvances in cancer vaccine development.Immunotherapy of hepatocellular carcinoma.Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer.MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.Codominant interference, antieffectors, and multitarget drugs.Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity.Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer.EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions.CD33⁺/p-STAT1⁺ double-positive cell as a prognostic factor for stage IIIa gastric cancer.Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy.In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors.The clinical significance of systemic inflammation score in esophageal squamous cell carcinoma.
P2860
Q24810552-2E2417AE-A0C7-49F6-85B2-13860265EA27Q28280488-4383E1FD-BB74-4826-A4E8-9755AB7628BDQ33603404-A6C11782-6620-4C62-949C-70D633D7CAF5Q34534264-70670E66-8B75-4A71-940F-6BFE0CA89784Q34734131-46A71BE4-DF5C-40DB-BBAB-261858590F8CQ35764937-CE1AABE6-0DF2-421C-8BD5-7C060680F3BAQ35903086-CAC1871D-6464-44A6-AEB1-72BED72E4DE0Q36142259-235B6756-8CF9-44FA-8993-BCB5DC7CDE4EQ36250686-D084B021-F571-484A-B3A1-F5100EC4E041Q36623198-3A5D4F2D-25FC-4C9C-A1F8-9854F8969681Q36651018-DCA2ACE5-FFA9-4F93-A6FD-B4568350DC79Q36694163-D15CA7EF-866E-47B0-8ACA-5C956150408AQ36895039-71170CB9-84DB-4032-A58A-AF0D08AED41EQ37186903-83A34F86-B446-4A48-BAC4-69C9D5F75A50Q38465242-4C9F7667-BA55-421A-8669-6D878A7CB335Q38471940-9D8C1A79-3989-4E51-BEC1-1C1BCA0D3743Q39506976-8516B5BD-3811-48D5-8AD1-236299FD37CAQ39904721-58387A15-24E3-4451-BB91-A06AFB22E1CAQ40375567-ACBAFAF7-E8F1-47AE-AAEC-2CC3232FAC8BQ41283233-E9ABCE3D-5868-40B8-A1E5-B62C9B057FA8
P2860
The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
The immunotherapy of solid can ...... ding tumor-rejection antigens.
@en
type
label
The immunotherapy of solid can ...... ding tumor-rejection antigens.
@en
prefLabel
The immunotherapy of solid can ...... ding tumor-rejection antigens.
@en
P1476
The immunotherapy of solid can ...... ding tumor-rejection antigens.
@en
P2093
Rosenberg SA
P304
P356
10.1146/ANNUREV.MED.47.1.481
P577
1996-01-01T00:00:00Z